2013年-世界发展银行全球_Advancing_Cervical_Cancer_Prevention_in_India___Insights_from_Research_and_Programs_68页_1mb

Summary of "Advancing Cervical Cancer Prevention in India: Insights from Research and Programs"

Background

Cervical cancer is the leading cause of cancer mortality among Indian women aged 30 to 69, accounting for 17% of all cancer deaths in this group. In 2008, India accounted for a quarter of the global cervical cancer incidence and mortality. Despite advancements in health care and research, there has been little progress in reducing cervical cancer mortality. Most cases are diagnosed at advanced stages, leading to poor outcomes. The Indian government launched a national program in 2011 to address chronic and non-communicable diseases, including cervical cancer screening and treatment. However, large-scale prevention programs remain limited.

Methods

The paper synthesizes findings from a review of peer-reviewed English-language publications, gray literature, and in-depth interviews with individuals involved in cervical cancer prevention programs and research in India. The review included studies from 1990 to 2013, focusing on screening, early detection, HPV, and visual inspection techniques. Interviews were conducted with public health officials, cancer experts, and non-governmental initiative participants in Tamil Nadu, Kerala, and Karnataka.

Core Content

Primary Prevention: HPV Vaccination

• HPV Transmission: HPV is easily transmitted, and most infections are cleared by the immune system, but some persist and can lead to cervical cancer.
• Available Vaccines: Two vaccines are available in India — Cervarix® (targets HPV 16 and 18) and GARDASIL® (targets 6, 11, 16, and 18). These vaccines are safe and effective, with only mild side effects.
• WHO Recommendations: WHO recommends HPV vaccination for girls aged 9–13 before sexual activity begins. However, due to partial efficacy and unknown duration of protection, screening remains essential.
• Cost and Accessibility: The vaccine is expensive (around $40 per dose), and subsidies are necessary for low- and middle-income countries. GAVI offers the vaccine at $4.50 per dose to eligible countries.
• Challenges: Strategies are needed to reach preadolescent girls, communicate vaccine information effectively, and ensure informed decision-making among parents and girls.
• Program Context: Currently, HPV vaccines are available through the private sector. Public provision is essential to ensure equitable access.

Secondary Prevention: Screening for Cervical Cancer

• Screening Approaches: Multiple screening methods have been evaluated, including visual inspection with acetic acid (VIA), visual inspection with Lugol’s iodine (VILI), Pap smear, and HPV DNA testing.
• Effectiveness: VIA and VILI have comparable sensitivity and specificity to Pap smear and HPV DNA testing. They are more feasible in resource-limited settings due to their simplicity and immediate results.
• Screen-and-Treat Model: This model allows for immediate treatment during the same visit, improving follow-up rates. However, it may lead to overtreatment due to lower specificity.
• Challenges in Uptake: Women often refuse screening due to fear of the procedure, lack of symptoms, cultural stigma, and logistical barriers such as long waiting times and male-dominated health services.
• Impact and Cost-Effectiveness: Studies show that VIA-based screening can significantly reduce cervical cancer mortality. Cost-effectiveness analyses indicate that VIA is the least expensive option, followed by cytology. HPV DNA testing is more expensive and less effective in detecting CIN2/3+.
• Linkages: Strong linkages between screening, diagnosis, and treatment are critical for program effectiveness.

Programmatic Experiences

• Tamil Nadu Health Systems Project (TNHSP): A state-level initiative supported by the World Bank, offering cervical cancer prevention services as part of broader chronic disease management. It demonstrated the feasibility of integrating cervical cancer prevention into public health systems.
• Chennai Corporation: A citywide program that also includes cervical cancer screening and treatment. Both programs focus on primary health care and aim to improve access to services.
• Program Outcomes: Despite high screening coverage (around 70%), follow-up and treatment rates were suboptimal. Only about half of the screen-positive women underwent further testing, and only 13% received treatment.
• Lessons Learned: Effective community mobilization, training of health workers, and local leadership are essential. Programs must be tailored to the local context and address women's concerns and constraints.

Recommendations

Leadership and Governance

• Increase political and administrative commitment to cervical cancer prevention.
• Develop and strengthen health information systems for monitoring and evaluation.
• Expand access to health services, especially for vulnerable populations.

Community Mobilization

• Train and sensitize local health workers on cervical cancer prevention.
• Engage local leaders and community groups to promote awareness and participation.
• Use culturally appropriate messages to address fears and misconceptions.
• Disseminate information through reliable channels.

Comprehensive and Cost-Effective Service Delivery

• Design programs that are "women-centered," addressing their needs and constraints.
• Combine primary and secondary prevention strategies based on performance and practicality.
• Ensure strong linkages between screening, diagnosis, and treatment services.
• Implement quality assurance mechanisms at all levels of care.
• Use prospective evaluation to improve program quality and effectiveness.

Conclusion

Research and programmatic experiences in India provide strong evidence for the effectiveness of cervical cancer prevention strategies, particularly screening and treatment programs. While HPV vaccination is a promising primary prevention tool, its implementation requires further research and advocacy. The success of cervical cancer prevention depends on overcoming logistical, cultural, and financial barriers, ensuring strong health system linkages, and promoting community engagement and awareness. Investment in these areas is essential to reduce the burden of cervical cancer in India.